tegsedi
Generic: INOTERSEN SODIUM
tegsedi: sourced relationships with 1 company · 1 FDA decision.
tegsedi evidence translation
What we can confirm
1 FDA record
What it means
Source-backed records connect tegsedi to AKCA; that link alone does not prove the drug works.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
How could tegsedi → AKCA affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
treatment of patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| AKCEA THERAPEUTICS, INC. (AKCA) treatment of patients with polyneuropathy of hereditary tran… | Approved |
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with tegsedi?
tegsedi has dated SEC/FDA relationship records for AKCEA THERAPEUTICS, INC..
What is tegsedi's latest FDA decision?
The most recent tracked FDA decision for tegsedi is Approval, dated October 5, 2018.